Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Receivables - Other (2016 - 2023)

Historic Receivables - Other for Usana Health Sciences (USNA) over the last 10 years, with Q4 2023 value amounting to $6.2 million.

  • Usana Health Sciences' Receivables - Other rose 1908.16% to $6.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $6.2 million, marking a year-over-year increase of 1908.16%. This contributed to the annual value of $6.2 million for FY2023, which is 1908.16% up from last year.
  • According to the latest figures from Q4 2023, Usana Health Sciences' Receivables - Other is $6.2 million, which was up 1908.16% from $5.2 million recorded in Q4 2022.
  • Usana Health Sciences' Receivables - Other's 5-year high stood at $6.3 million during Q1 2021, with a 5-year trough of $5.2 million in Q4 2022.
  • For the 3-year period, Usana Health Sciences' Receivables - Other averaged around $5.9 million, with its median value being $6.2 million (2023).
  • Data for Usana Health Sciences' Receivables - Other shows a peak YoY increase of 1908.16% (in 2023) and a maximum YoY decrease of 1908.16% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Usana Health Sciences' Receivables - Other stood at $6.3 million in 2021, then fell by 17.1% to $5.2 million in 2022, then increased by 19.08% to $6.2 million in 2023.
  • Its last three reported values are $6.2 million in Q4 2023, $5.2 million for Q4 2022, and $6.3 million during Q1 2021.